Clinical trial
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement…
NCT00329628 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00329628 |
|---|---|
| Title | Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin |
| Official title | RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Venous Thromboembolism |
| Intervention type | Drug |
| Interventions | Rivaroxaban (BAY59-7939), Enoxaparin |
| Enrollment | 4,541 |
| Start date | Feb 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | May 25, 2006 |
| Last update posted | Oct 28, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France and 16 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: